EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CRISPR-Cas based plasmid design for multidrug-resistant Klebsiella pneumoniae isolates

Sevinc Baba, Oral Oncul, Zerrin Aktas

FEMS Microbiology Letters · 2026

DOI: 10.1093/femsle/fnag026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEMS Microbiology Letters, 2026. Verfasst von Sevinc Baba und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, Institute of Health Sciences, Istanbul University, 34093 Istanbul, Türkiye. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Plasmids, Drug Resistance, Multiple, Bacterial, CRISPR-Cas Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Istanbul University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimicrobial resistance is a major global health concern that requires innovative therapeutic strategies. This study aimed to address this challenge by designing Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated protein (CRISPR-Cas)-based plasmid systems for potential genome editing applications in multidrug-resistant (MDR) Klebsiella pneumoniae clinical isolates. Minimum inhibitory concentrations (MICs) of imipenem, meropenem, and ertapenem were determined according to European Committee on Antimicrobial Susceptibility Testing guidelines. All isolates (n = 5) were resistant, with MIC ranges of 4–128 μg/ml for imipenem, 8–64 μg/ml for meropenem, and 8–256 μg/ml for ertapenem. Resistance gene analysis revealed blaOXA-48-like and blaCTX-M-15 in all isolates, while blaNDM-1 was detected in one isolate. Two CRISPR-based plasmid systems, CRISPR-Cas9 and CRISPR-assisted cytidine deaminase, were designed. Target genes were amplified by polymerase chain reaction, and guide RNA (gRNA) sequences were designed from selected regions. Apramycin (50 μg/ml) was identified as a suitable selection marker. The pSGKP–AmpR(Pro)–ApmR plasmid was successfully constructed, whereas Cas9 and APOBEC constructs could not be cloned. Overall, this study highlights technical challenges in developing CRISPR-based tools for MDR K. pneumoniae and emphasizes the need for isolate-specific plasmid design and gRNA optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaePlasmidsDrug Resistance, Multiple, BacterialCRISPR-Cas SystemsAnti-Bacterial AgentsMicrobial Sensitivity Testsbeta-LactamasesKlebsiella InfectionsHumansImipenemGene EditingBacterial Proteins

Stichwörter der Autor:innen

Klebsiella pneumoniaeCRISPR-Cas systemscarbapenemaseplasmids

Substanzen

Anti-Bacterial Agentsbeta-LactamasesImipenemBacterial Proteins

Autor:innen und Institutionen

  • Department of Clinical Microbiology, Institute of Health Sciences, Istanbul University, 34093 Istanbul, Türkiye.
  • Life Sciences and Biomedical Engineering Application and Research Centre, Istanbul Gelisim University, 34310 Istanbul, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Türkiye.
  • Department of Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Türkiye.

Förderung

  • Istanbul University

Zitieren

APA

Baba, S., Oncul, O., & Aktas, Z. (2026). CRISPR-Cas based plasmid design for multidrug-resistant Klebsiella pneumoniae isolates. FEMS Microbiology Letters. https://doi.org/10.1093/femsle/fnag026

Vancouver

Baba S, Oncul O, Aktas Z. CRISPR-Cas based plasmid design for multidrug-resistant Klebsiella pneumoniae isolates. FEMS Microbiology Letters. 2026. doi:10.1093/femsle/fnag026

BibTeX
@article{Baba2026,
  author = {Baba, Sevinc and Oncul, Oral and Aktas, Zerrin},
  title = {CRISPR-Cas based plasmid design for multidrug-resistant Klebsiella pneumoniae isolates},
  journal = {FEMS Microbiology Letters},
  year = {2026},
  doi = {10.1093/femsle/fnag026}
}
Kostenlos starten →